本瑞利珠单抗治疗重度未控制哮喘的长期安全性与疗效:BORA 3期扩展试验1年结果
BORA是一项在24国447个中心开展的随机双盲3期扩展研究,纳入完成SIROCCO或CALIMA试验的重度未控制嗜酸性哮喘患者,评估本瑞利珠单抗30 mg每4周或每8周给药的安全性。全分析集1576例,最常见不良事件为病毒性上呼吸道感染(14-16%)和哮喘加重(7-10%),安全性与前一年一致,未见长期嗜酸性粒细胞耗竭的新后果。
要点
- 本瑞利珠单抗30 mg Q4W或Q8W长期治疗安全性良好,不良事件谱与既往一致。
- 最常见不良事件为病毒性上呼吸道感染(14-16%)和哮喘加重(7-10%)。
- 长期嗜酸性粒细胞耗竭未出现新的安全性后果,机会性感染发生率无增加。
核心结论
- 2年安全性结果验证本瑞利珠单抗第一年的观察在第二年治疗中持续存在。
- 未出现长期嗜酸性粒细胞耗竭的新后果,机会性感染等不良事件发生率在第二年相似。
研究设计与样本
- 随机、双盲、平行组、3期扩展研究,在24个国家447个中心开展。
- 纳入完成SIROCCO或CALIMA试验且继续接受本瑞利珠单抗30 mg Q4W或Q8W的重度未控制嗜酸性哮喘患者。
- 既往安慰剂组患者按1:1重新随机分配至本瑞利珠单抗30 mg Q4W或Q8W(前三次给药间隔4周)。
- 成人(≥18岁)治疗56周,青少年(12-17岁)治疗108周;主要终点为安全性耐受性,成人评估至68周,青少年至56周。
- 全分析集1576例,包括Q4W组783例(新分配265例)和Q8W组793例(新分配281例)。
主要发现
- 所有组最常见不良事件为病毒性上呼吸道感染(14-16%)和哮喘加重(7-10%)。
- 最常见严重不良事件为哮喘加重(3-4%)、肺炎(<1%至1%)和细菌性肺炎(0-1%)。
- 任何治疗中出现不良事件、严重不良事件或导致停药的不良事件百分比,在原本瑞利珠单抗组与原安慰剂组之间以及两种给药方案之间相似。
- 任何不良事件百分比在SIROCCO或CALIMA(71-75%,仅本瑞利珠单抗组)与BORA(65-71%)之间相似。
- 导致治疗停药的不良事件百分比在SIROCCO和CALIMA为2%,在BORA为2-3%。
临床怎么用
- 本瑞利珠单抗30 mg Q4W或Q8W长期用于重度未控制嗜酸性哮喘患者安全性可接受。
- 长期治疗期间需关注病毒性上呼吸道感染、哮喘加重及肺炎等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patients with severe, uncontrolled eosinophilic asthma. METHODS: We conducted a randomised, double-blind, parallel-group, phase 3 extension study at 447 sites in 24 countries. Eligible patients had to have completed the SIROCCO or CALIMA trials and remained on subcutaneous benralizumab 30 mg every 4 weeks (Q4W) or every 8 weeks (Q8W). Patients who had received placebo in those trials were re-randomised in a 1:1 ratio, using an interactive web-based system, to benralizumab 30 mg either Q4W or Q8W (first three doses 4 weeks apart). Treatment lasted for 56 weeks for adult patients (age ≥18 years) and 108 weeks for adolescent patients (age 12-17 years). The primary endpoint was the safety and tolerability of the two dosing regimens of benralizumab up to 68 weeks for adult patients (including the follow-up visit post-treatment) and up to 56 weeks for adolescent patients. This endpoint was assessed in the full analysis set, which included all patients from the SIROCCO and CALIMA predecessor studies who received at least one dose of study treatment in BORA and did not continue into another trial. This study is registered with ClinicalTrials.gov (NCT02258542). FINDINGS: Between Nov 19, 2014, and July 6, 2016, we enrolled 1926 patients, of whom 633 had received benralizumab Q4W and 639 had received benralizumab Q8W in SIROCCO or CALIMA. The remaining 654 patients had received placebo in those trials and were randomly re-assigned in this trial to receive benralizumab Q4W (n=320) or Q8W (n=334). 1576 patients, including 783 who received benralizumab Q4W (265 newly assigned) and 793 who received benralizumab Q8W (281 newly assigned), were included in the full analysis set. The most common adverse events in all groups were viral upper respiratory tract infection (14-16%) and worsening asthma (7-10%). The most common serious adverse events were worsening asthma (3-4%), pneumonia (<1% to 1%), and pneumonia caused by bacterial infection (0-1%). The percentages of patients who had any on-treatment adverse event, any serious adverse event, or any adverse event leading to treatment discontinuation during BORA were similar between patients originally assigned benralizumab and those originally assigned placebo and between benralizumab treatment regimens. The percentage of patients who had any adverse event was similar between SIROCCO or CALIMA (71-75%; benralizumab group only) and BORA (65-71%), as was the percentage of patients who had an adverse event that led to treatment discontinuation (2% in SIROCCO and CALIMA vs 2-3% in BORA). INTERPRETATION: The 2 years of safety results validate that observations observed in the first year of benralizumab continued through a second year of treatment. No new consequences of long-term eosinophil depletion occurred, and the incidence of other adverse events, including opportunistic infections, were similar during the second year. FUNDING: AstraZeneca and Kyowa Hakko Kirin.
引用
- Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2018. PMID: 30416083. doi:10.1016/S2213-2600(18)30406-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。